SEC Comment Letter for SOLIGENIX, INC. (SNGX) (CIK 0000812796) (SNGX) — Nov 28, 2017
SOLIGENIX, INC. (SNGX) (CIK 0000812796)
Date: Nov. 28, 2017 · CIK: 0000812796 · Accession: 0000000000-17-041760
AI Filing Summary & Sentiment
Reasoning
Letter
November 28, 2017 Christopher J. Schaber President and Chief Executive Officer Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 Soligenix, Inc. Registration Statement on Form S-1 Filed November 20, 2017 File No. 333-221681Re: Dear Dr. Schaber: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at (202) 551-5019 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Driscoll R. Ugarte, Esq.
Show Raw Text
November 28, 2017
Christopher J. Schaber
President and Chief Executive Officer
Soligenix, Inc.
29 Emmons Drive, Suite B-10
Princeton, NJ 08540
Soligenix, Inc.
Registration Statement on Form S-1
Filed November 20, 2017
File No. 333-221681Re:
Dear Dr. Schaber:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at (202) 551-5019 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Driscoll R. Ugarte, Esq.